Preventing the misfolding, aggregation, accumulation and propagation of α-synuclein — pivotal mechanisms that contribute to neurodegeneration in Parkinson disease (PD) and other synucleinopathies — is the ultimate goal of research into neuroprotective therapy. Now, exenatide, a glucagon-like peptide-1 (GLP-1) agonist, has been reported to ameliorate the severity of motor symptoms associated with PD.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A GLP1 receptor agonist diabetes drug ameliorates neurodegeneration in a mouse model of infantile neurometabolic disease
Scientific Reports Open Access 15 August 2022
-
Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease
Scientific Reports Open Access 16 July 2018
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Rousseaux, M. W., Shulman, J. M. & Jankovic, J. Progress toward an integrated understanding of Parkinson's disease. F1000Res. 6, 1121 (2017).
Athauda, D. et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet http://dx.doi.org/10.1016/s0140-6736(17)31585-4 (2017).
Aviles-Olmos, I. et al. Exenatide and the treatment of patients with Parkinson's disease. J. Clin. Invest. 123, 2730–2736 (2013).
Athauda, D., Wyse, R., Brundin, P. & Foltynie, T. Is Exenatide a treatment for Parkinson's disease? J. Parkinsons Dis. 7, 451–458 (2017).
Bassil, F. et al. Insulin resistance and exendin-4 treatment for multiple system atrophy. Brain 140, 1420–1436 (2017).
Lu, L. et al. Diabetes and risk of Parkinson's disease: an updated meta-analysis of case-control studies. PLoS ONE 9, e85781 (2014).
Mattson, M. P. Interventions that improve body and brain bioenergetics for Parkinson's disease risk reduction and therapy. J. Parkinsons Dis. 4, 1–13 (2014).
Ghosh, A. et al. Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease. Sci. Transl. Med. 8, 368ra174 (2016).
NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 14, 795–803 (2015)
Lotia, M. & Jankovic, J. New and emerging medical therapies in Parkinson's disease. Expert Opin. Pharmacother. 17, 895–909 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.J. has received research and/or training grants from the Michael J. Fox Foundation for Parkinson's Research, the NIH, Neurocrine Biosciences, the Parkinson's Disease Foundation, Prothena Biosciences and Teva Pharmaceuticals. He has served as a consultant or as an advisory committee member for Allergan, Pfizer and Teva Pharmaceuticals.
Rights and permissions
About this article
Cite this article
Jankovic, J. Exenatide – a drug for diabetes and Parkinson disease?. Nat Rev Neurol 13, 643–644 (2017). https://doi.org/10.1038/nrneurol.2017.140
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2017.140
This article is cited by
-
A GLP1 receptor agonist diabetes drug ameliorates neurodegeneration in a mouse model of infantile neurometabolic disease
Scientific Reports (2022)
-
Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease
Scientific Reports (2018)